Cancer cells have the ability to establish a molecular shield, protecting against drugs and the host’s own immune defenses. This is accomplished by hijacking and reprogramming the surrounding healthy cells in the host tissue. Based on recent and cutting edge science, our overarching aim is now to develop a novel therapy that effectively destroys the shield and opens up the tumor for the host´s potent attack. This is immune oncology in its essence.
Our focal point of attack is represented by the target denoted LRRC15 (Leucin Rich Repeat Containing Protein 15). The tumor will be erased by our proprietary antibody molecule, designated mAb211.